EE571 Cost-Effectiveness of Maribavir for Post-Transplant Refractory Cytomegalovirus Infection With or Without Resistance: A UK Perspective

Abstract

Cytomegalovirus (CMV) infection is associated with morbidity and mortality following solid organ or hematopoietic cell transplant (SOT/HCT). Toxicities and development of refractory (with or without resistance [R/R]) CMV limit current anti-CMV agents use. In the Phase 3 SOLSTICE (NCT02931539) study of R/R CMV infection in SOT/HCT recipients, maribavir achieved superior efficacy (CMV viremia clearance) with an improved safety profile against investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir). This analysis investigates the cost-effectiveness of maribavir versus IAT for treatment of post-transplant R/R CMV.